CoChat

Cost-Effectiveness of Treatments for Adolescent Depression: Results From TADS

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: While the evidence base for treatments for adolescent depression is building, little is known about the relative efficiency of such treatments. Treatment costs are a relevant concern given the competing demands on family and health care budgets. The authors evaluated the cost-effectiveness of three active treatments among adolescents with major depressive disorder. METHOD: Volunteers (N=439) ages 12 to 18 with a primary diagnosis of major depressive disorder participated in a randomized, controlled trial conducted at 13 U.S. academic and community clinics from 2000 to 2004. Subjects included those participants who did not drop out and had evaluable outcome and cost data at 12 weeks (N=369). Subjects were randomly assigned to 12 weeks of either fluoxetine alone (10-40 mg/day), CBT alone, CBT combined with fluoxetine (10-40 mg/day), or placebo (equivalent to 10-40 mg/day). Both placebo and fluoxetine were administered double-blind; CBT alone and CBT in combination with fluoxetine were administered unblinded. Societal cost per unit of improvement on the Children's Depression Rating Scale-Revised and cost per quality-adjusted life year (QALY) were compared. RESULTS: Results ranged from an incremental cost over placebo of $24,000 per QALY for treatment with fluoxetine to $123,000 per QALY for combination therapy treatment. The cost-effectiveness ratio for CBT treatment was not evaluable due to negative clinical effects. The models were robust on a variety of assumptions. CONCLUSIONS: Both fluoxetine and combination therapy are at least as cost-effective in the short-term as other treatments commonly used in primary care (using a threshold of $125,000/QALY). Fluoxetine is more cost-effective than combination therapy after 12 weeks of treatment.

Overview

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2008.07101610

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Research works printed but not linked: 4

  1. Essau C, 1999, NJ, Jason Aronson, 69
  2. March J, JAMA 2004; 292: 807-820
  3. Gold MR, 1996, Russell LB
  4. Poznanski EO, 1996, Mokros HB: Children's Depression Rating Scale-Revised

Cited by

See all 92

Metadata

Authors
Domino, M. E., Burns, B. J., Silva, S. G., Kratochvil, C. J., Vitiello, B., Reinecke, M. A., Mario, J., & March, J. S.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Suburban Hospital (US)
Venue
American Journal of Psychiatry
Published
2008-05
Volume
165
Issue
5
Pages
588-596
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2121303532
Cited by
92
References
30
Citations by year
2026: 1 · 2025: 4 · 2024: 5 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 1 · 2019: 2 · 2018: 5 · 2017: 4 · 2016: 5 · 2015: 5 · 2014: 7 · 2013: 4 · 2012: 3
FWCI
29.92
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
Funders
  • National Institutes of Health (n01mh080008-004)
  • National Institute of Mental Health (N01 MH 80008, K01MH065639)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
adolescent depression, major depressive disorder, cost-effectiveness, fluoxetine, cognitive behavioral therapy, combination therapy, quality-adjusted life years, Children's Depression Rating Scale-Revised, treatment costs, primary care
MeSH terms
Adolescent, Child, Combined Modality Therapy, Cost-Benefit Analysis, Major Depressive Disorder, Drug Therapy, Female, Fluoxetine, Humans, Male, Primary Health Care, Psychotherapy, Treatment Outcome, Selective Serotonin Reuptake Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost-Effectiveness of Treatments for Adolescent Depression: Results From TADS. https://app.cochat.ai/papers/10.1176/appi.ajp.2008.07101610
The paper
Domino, M. E., Burns, B. J., Silva, S. G., Kratochvil, C. J., Vitiello, B., Reinecke, M. A., Mario, J., & March, J. S. (2008). Cost-Effectiveness of Treatments for Adolescent Depression: Results From TADS. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2008.07101610

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.